Compare Stocks: ASMB, ANIP, OCUL, and CMPS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$72.29 +0.0%	$73.59	$69.58 ▼ $97.00	$1.66B	0.5	412,460 shs	333,921 shs
ASMB Assembly Biosciences	$20.09 -2.3%	$28.27	$19.94 ▼ $39.71	$409.05M	1.15	339,054 shs	167,735 shs
CMPS Compass Pathways	$10.75 -7.5%	$13.30	$4.88 ▼ $15.87	$1.49B	2.55	2.72 million shs	4.97 million shs
OCUL Ocular Therapeutix	$6.87 -6.9%	$9.56	$6.23 ▼ $16.44	$1.51B	1	3.96 million shs	2.76 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	0.00%	-2.17%	-4.11%	-8.72%	-19.77%
ASMB Assembly Biosciences	0.00%	-14.62%	-20.72%	-25.07%	-29.36%
CMPS Compass Pathways	0.00%	-10.42%	-28.33%	-12.96%	+57.39%
OCUL Ocular Therapeutix	0.00%	-8.89%	-32.25%	-23.41%	-42.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$72.29 +0.0%	$73.59	$69.58 ▼ $97.00	$1.66B	0.5	412,460 shs	333,921 shs
ASMB Assembly Biosciences	$20.09 -2.3%	$28.27	$19.94 ▼ $39.71	$409.05M	1.15	339,054 shs	167,735 shs
CMPS Compass Pathways	$10.75 -7.5%	$13.30	$4.88 ▼ $15.87	$1.49B	2.55	2.72 million shs	4.97 million shs
OCUL Ocular Therapeutix	$6.87 -6.9%	$9.56	$6.23 ▼ $16.44	$1.51B	1	3.96 million shs	2.76 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	0.00%	-2.17%	-4.11%	-8.72%	-19.77%
ASMB Assembly Biosciences	0.00%	-14.62%	-20.72%	-25.07%	-29.36%
CMPS Compass Pathways	0.00%	-10.42%	-28.33%	-12.96%	+57.39%
OCUL Ocular Therapeutix	0.00%	-8.89%	-32.25%	-23.41%	-42.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	2.43	Hold	$99.60	37.78% Upside
ASMB Assembly Biosciences	2.83	Moderate Buy	$47.50	136.44% Upside
CMPS Compass Pathways	2.88	Moderate Buy	$23.36	117.28% Upside
OCUL Ocular Therapeutix	2.83	Moderate Buy	$22.86	232.71% Upside

Current Analyst Ratings Breakdown

Latest ASMB, ANIP, OCUL, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	ASMB Assembly Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	CMPS Compass Pathways	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	OCUL Ocular Therapeutix	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/11/2026	OCUL Ocular Therapeutix	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$14.00
10/11/2026	OCUL Ocular Therapeutix	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/2/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$23.00
9/29/2026	OCUL Ocular Therapeutix	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
9/29/2026	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$18.00
9/23/2026	ANIP ANI Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Perform	$85.00
9/16/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$23.00
9/16/2026	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$25.00

(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$883.37M	1.88	$9.93 per share	7.28	$24.03 per share	3.01
ASMB Assembly Biosciences	$72.30M	5.66	N/A	N/A	$13.04 per share	1.54
CMPS Compass Pathways	N/A	N/A	N/A	N/A	($0.55) per share	N/A
OCUL Ocular Therapeutix	$52.06M	28.98	N/A	N/A	$3.07 per share	2.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	$78.34M	$4.64	15.58	8.60	2.33	11.07%	27.37%	10.47%	11/6/2026 (Estimated)
ASMB Assembly Biosciences	-$6.12M	$1.02	19.70	401.80	N/A	-0.06%	-0.02%	-0.02%	11/9/2026 (Estimated)
CMPS Compass Pathways	-$287.86M	-$4.62	N/A	N/A	N/A	N/A	-49.63%	-13.08%	11/3/2026 (Estimated)
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)

Latest ASMB, ANIP, OCUL, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	ASMB Assembly Biosciences	-$0.6550	N/A	N/A	N/A	$9.07 million	N/A
11/6/2026	Q3 2026	ANIP ANI Pharmaceuticals	$2.18	N/A	N/A	N/A	$280.25 million	N/A
11/3/2026	Q3 2026	CMPS Compass Pathways	-$0.3629	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	OCUL Ocular Therapeutix	-$0.3648	N/A	N/A	N/A	$14.27 million	N/A
8/13/2026	Q2 2026	ASMB Assembly Biosciences	-$0.7242	-$0.20	+$0.5242	-$0.20	$8.60 million	$13.37 million
8/7/2026	Q2 2026	ANIP ANI Pharmaceuticals	$2.04	$2.21	+$0.17	$1.05	$260.13 million	$266.04 million
8/5/2026	Q2 2026	CMPS Compass Pathways	-$0.3881	-$1.88	-$1.4919	-$1.88	N/A	N/A
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
CMPS Compass Pathways	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	0.99	2.91	2.41
ASMB Assembly Biosciences	N/A	13.99	13.99
CMPS Compass Pathways	0.60	1.30	1.30
OCUL Ocular Therapeutix	0.14	13.10	13.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
ASMB Assembly Biosciences	19.92%
CMPS Compass Pathways	46.19%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	8.10%
ASMB Assembly Biosciences	3.50%
CMPS Compass Pathways	2.82%
OCUL Ocular Therapeutix	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	970	22.97 million	21.11 million	Optionable
ASMB Assembly Biosciences	73	20.36 million	19.65 million	Optionable
CMPS Compass Pathways	156	138.48 million	134.57 million	Optionable
OCUL Ocular Therapeutix	325	219.62 million	212.81 million	Optionable

ASMB, ANIP, OCUL, and CMPS Headlines

Recent News About These Companies

Ocular Therapeutix, Inc. (OCUL) Presents at American Academy of Ophthalmology Retina Subspeciality Day - Slideshow

October 15 at 7:01 PM | seekingalpha.com

Ocular Therapeutix (NASDAQ:OCUL) Stock Lifted to "Strong-Buy" by UBS Group

October 14, 2026 | marketbeat.com

Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

October 14, 2026 | theglobeandmail.com

Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Todd Anderman Sells 11,984 Shares

October 13, 2026 | marketbeat.com

Ocular Therapeutix, Inc. (OCUL) - What Are Brokerages Thinking About This Stock?

October 11, 2026 | americanbankingnews.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Has Average Price Target of $24.33 According to Brokerages

October 11, 2026 | marketbeat.com

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2026 | globenewswire.com

Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Jeffrey Heier Sells 10,869 Shares

October 8, 2026 | americanbankingnews.com

Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Peter Kaiser Sells 9,990 Shares

October 7, 2026 | insidertrades.com

Ocular Therapeutix, Inc. (OCUL) Presents at Euretina 2026 - Slideshow

October 6, 2026 | seekingalpha.com

Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $70,429.50 in Stock

October 6, 2026 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Insider Sells 10,869 Shares of Company Stock

October 6, 2026 | marketbeat.com

Stocktwits Pharma Pulse: Roche faces FDA decision, gene-therapy stocks step into focus — the week’s biotech watchlist

October 4, 2026 | msn.com

Ocular Therapeutix Executive Files Form 144 to Sell 10,869 Shares of Common Stock

October 4, 2026 | kalkinemedia.comK

Chardan Keeps Ocular Therapeutix Buy, $23 Target

October 3, 2026 | ijr.comI

Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws Scrutiny

October 2, 2026 | finance.yahoo.com

Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital

October 2, 2026 | marketbeat.com

OCUL stock on track for worst week in 2.5 years as rivals raise the bar in wet AMD

October 2, 2026 | msn.com

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

October 1, 2026 | globenewswire.com

Ocular Therapeutix stock price

September 29, 2026 | ijr.comI

Ocular Therapeutix (NASDAQ:OCUL) Given "Buy" Rating at Needham & Company LLC

September 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB, ANIP, OCUL, and CMPS Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$72.29 +0.01 (+0.01%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$72.34 +0.05 (+0.08%)

As of 10/16/2026 07:30 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Assembly Biosciences NASDAQ:ASMB

$20.09 -0.48 (-2.33%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$20.12 +0.03 (+0.15%)

As of 10/16/2026 07:30 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Compass Pathways NASDAQ:CMPS

$10.75 -0.87 (-7.49%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$10.91 +0.16 (+1.49%)

As of 10/16/2026 07:55 PM Eastern

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Ocular Therapeutix NASDAQ:OCUL

$6.87 -0.51 (-6.91%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$6.97 +0.10 (+1.47%)

As of 10/16/2026 07:30 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASMB, ANIP, OCUL, and CMPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASMB, ANIP, OCUL, and CMPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASMB, ANIP, OCUL, and CMPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB, ANIP, OCUL, and CMPS Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

Assembly Biosciences NASDAQ:ASMB

Compass Pathways NASDAQ:CMPS

Ocular Therapeutix NASDAQ:OCUL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASMB, ANIP, OCUL, and CMPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASMB, ANIP, OCUL, and CMPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASMB, ANIP, OCUL, and CMPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB, ANIP, OCUL, and CMPS Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

Assembly Biosciences NASDAQ:ASMB

Compass Pathways NASDAQ:CMPS

Ocular Therapeutix NASDAQ:OCUL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools